About the Study
This study is designed to evaluate the safety and effectiveness of RO7795068, an investigational injection, for chronic weight management in adults who have obesity or who are overweight, without type 2 diabetes mellitus. RO7795068 is an “investigational” drug because it has not been approved by the Food and Drug Administration (FDA).
The study is randomized, double-blind, and placebo-controlled to ensure high-quality, unbiased results. If you qualify and choose to participate, there is a 75% chance you will receive the study treatment and a 25% chance you will receive a placebo. A placebo is an inactive material that looks like the study drug but does not contain any active ingredient.
You will be on this study for approximately 79 weeks which will include a screening period, a treatment period, and a follow up period. The study will require up to 16 in-clinic visits and 6 remote visits. If you qualify and choose to participate, you may be compensated for up to $3,284 for your study-related time and travel. There may also be a possibility to join an open label extension following participation where the active drug will be received for anyone completing the core study. Your participation is entirely voluntary, and you can leave the study at any time.